|
1
|
Gabrilovich DI and Nagaraj S:
Myeloid-derived suppressor cells as regulators of the immune
system. Nat Rev Immunol. 9:162–174. 2009.
|
|
2
|
Yang L, DeBusk LM, Fukuda K, Fingleton B,
Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP and Lin PC:
Expansion of myeloid immune suppressor Gr+CD11b+ cells in
tumor-bearing host directly promotes tumor angiogenesis. Cancer
Cell. 6:409–421. 2004.
|
|
3
|
Ostrand-Rosenberg S and Sinha P:
Myeloid-derived suppressor cells: linking inflammation and cancer.
J Immunol. 182:4499–4506. 2009.
|
|
4
|
Yang R, Cai Z, Zhang Y, Yutzy WH IV, Roby
KF and Roden RB: CD80 in immune suppression by mouse ovarian
carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res.
66:6807–6815. 2006.
|
|
5
|
Huang B, Pan PY, Li Q, Sato AI, Levy DE,
Bromberg J, Divino CM and Chen SH: Gr-1+CD115+ immature myeloid
suppressor cells mediate the development of tumor-induced T
regulatory cells and T-cell anergy in tumor-bearing host. Cancer
Res. 66:1123–1131. 2006.
|
|
6
|
Serafini P, Mgebroff S, Noonan K and
Borrello I: Myeloid-derived suppressor cells promote
cross-tolerance in B-cell lymphoma by expanding regulatory T Cells.
Cancer Res. 68:5439–5449. 2008.
|
|
7
|
Greenwald RJ, Freeman GJ and Sharpe AH:
The B7 family revisited. Annu Rev Immunol. 23:515–548. 2005.
|
|
8
|
Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang
G, Yin B, Divino CM and Chen SH: Immune stimulatory receptor CD40
is required for T-cell suppression and T regulatory cell activation
mediated by myeloid-derived suppressor cells in cancer. Cancer Res.
70:99–108. 2010.
|
|
9
|
Sinha P, Chornoguz O, Clements VK,
Artemenko KA, Zubarev RA and Ostrand-Rosenberg S: Myeloid-derived
suppressor cells express the death receptor Fas and apoptose in
response to T cell-expressed FasL. Blood. 117:5381–5390. 2011.
|
|
10
|
Rizvi M, Pathak D, Freedman JE and
Chakrabarti S: CD40-CD40 ligand interactions in oxidative stress,
inflammation and vascular disease. Trends Mol Med. 14:530–538.
2008.
|
|
11
|
Van Kooten C and Banchereau J: CD40-CD40
ligand. J Leukoc Biol. 67:2–17. 2000.
|
|
12
|
Murugaiyan G, Martin S and Saha B:
CD40-induced countercurrent conduits for tumor escape or
elimination? Trends Immunol. 28:467–473. 2007.
|
|
13
|
Schlom J, Jochems C, Gulley JL and Huang
J: The role of soluble CD40L in immunosuppression. Oncoimmunology.
2:e225462013.
|
|
14
|
Huang J, Jochems C, Talaie T, Anderson A,
Jales A, Tsang KY, Madan RA, Gulley JL and Schlom J: Elevated serum
soluble CD40 ligand in cancer patients may play an
immunosuppressive role. Blood. 120:3030–3038. 2012.
|
|
15
|
Roth F, De La Fuente AC, Vella JL, Zoso A,
Inverardi L and Serafini P: Aptamer-mediated blockade of IL4Rα
triggers apoptosis of MDSCs and limits tumor progression. Cancer
Res. 72:1373–1383. 2012.
|
|
16
|
Ribechini E, Leenen PJ and Lutz MB: Gr-1
antibody induces STAT signaling, macrophage marker expression and
abrogation of myeloid-derived suppressor cell activity in BM cells.
Eur J Immunol. 39:3538–3551. 2009.
|
|
17
|
Vincent J, Mignot G, Chalmin F, Ladoire S,
Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C and
Ghiringhelli F: 5-Fluorouracil selectively kills tumor-associated
myeloid-derived suppressor cells resulting in enhanced T
cell-dependent antitumor immunity. Cancer Res. 70:3052–3061.
2010.
|
|
18
|
Veltman JD, Lambers ME, van Nimwegen M,
Hendriks RW, Hoogsteden HC, Aerts JG and Hegmans JP: COX-2
inhibition improves immunotherapy and is associated with decreased
numbers of myeloid-derived suppressor cells in mesothelioma.
Celecoxib influences MDSC function. BMC Cancer. 10:4642010.
|
|
19
|
Weiss JM, Back TC, Scarzello AJ, Subleski
JJ, Hall VL, Stauffer JK, Chen X, Micic D, Alderson K, Murphy WJ
and Wiltrout RH: Successful immunotherapy with IL-2/anti-CD40
induces the chemokine-mediated mitigation of an immunosuppressive
tumor microenvironment. Proc Natl Acad Sci USA. 106:19455–19460.
2009.
|
|
20
|
Zhao X, Rong L, Zhao X, Li X, Liu X, Deng
J, Wu H, Xu X, Erben U, Wu P, et al: TNF signaling drives
myeloid-derived suppressor cell accumulation. J Clin Invest.
122:4094–4104. 2012.
|
|
21
|
Youn JI, Nagaraj S, Collazo M and
Gabrilovich DI: Subsets of myeloid-derived suppressor cells in
tumor-bearing mice. J Immunol. 181:5791–5802. 2008.
|
|
22
|
Ostrand-Rosenberg S, Sinha P, Chornoguz O
and Ecker C: Regulating the suppressors: apoptosis and inflammation
govern the survival of tumor-induced myeloid-derived suppressor
cells (MDSC). Cancer Immunol Immunother. 61:1319–1325. 2012.
|
|
23
|
Humphreys EH, Williams KT, Adams DH and
Afford SC: Primary and malignant cholangiocytes undergo CD40
mediated Fas dependent apoptosis, but are insensitive to direct
activation with exogenous Fas ligand. PLoS One. 5:e140372010.
|
|
24
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: a leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009.
|
|
25
|
Ahmed-Choudhury J, Williams KT, Young LS,
Adams DH and Afford SC: CD40 mediated human cholangiocyte apoptosis
requires JAK2 dependent activation of STAT3 in addition to
activation of JNK1/2 and ERK1/2. Cell Signal. 18:456–468. 2006.
|
